The Name on the Frames: Who Owns Eye Care, and What Changes When It's Bought
Private equity has bought eye surgeons' and optometrists' practices, and one company makes many of the lenses, owns or licenses many of the frame brands, runs large optical chains and owns a vision insurer. Who the owners are, what studies found after practices were bought, what has happened to prices, where specialists are scarce, the lawsuits, California's rules, and what each side argues.
November 5, 2026
The short version
Eye care has two kinds of big owners. Private equity firms have bought ophthalmology practices, where surgeons treat cataracts, glaucoma and retina disease, and optometry offices, where most people get their exams and glasses: hundreds of purchases since 2012, most of them after 2016. Estimates of their reach run from about 5% to 17% of ophthalmologists, depending on the method and the year, but nearly 30% of retina specialists are affiliated with private equity. After purchases, studies found higher prices paid by commercial insurers, more use of an expensive retina drug, and 19.6% fewer retinal-detachment repairs, a surgery Medicare pays less for than it costs. On the other side of the counter, EssilorLuxottica makes Varilux, Crizal and Transitions lenses, owns Ray-Ban and Oakley, makes frames for Chanel and Prada, runs LensCrafters, Pearle Vision, Target Optical and Sunglass Hut, and owns the vision plan EyeMed; its main rival, VSP, owns frame makers, labs and its own chains. Meanwhile, the price index for eyeglasses and eye care has risen about half as fast as consumer prices overall since 2000. One of the largest eye care groups, EyeCare Partners, is selling its more than 300 optometry offices to pay down debt, and drug distributors have begun buying eye practices.
New articles and charts arrive in one short email on Monday mornings. Get the weekly digest
The analogy
A supermarket chain that also owns the farms, the brands on the shelves and the coupon program its customers pay with. Shoppers see a familiar store and familiar labels; the same company is on several sides of the sale.
The farms are the lens factories and frame makers, the shelf brands are Ray-Ban, Oakley and the fashion labels, the supermarket is the optical chain, and the coupon program is the vision plan. The eye doctor whose office is inside or next to the store is usually a separate business, and that business, too, may now belong to an investor.
Figures below are as of early November 2026.
How big the field is
There were 21,387 private optometrists' offices with employees in 2025, up from 20,670 in 2016, employing about 155,000 people (BLS, establishments; BLS, employees). Optometrists who work in optical stores are counted with the stores, and ophthalmologists' practices are counted with other physicians' offices. The BLS counted 45,100 optometrist jobs in 2025, with median pay of $136,570; 61% worked in optometrists' offices, 14% in physicians' offices and 13% in stores (BLS).
How much private equity owns depends on who is counting:
- A Harvard-led study counted 228 purchases of eye practices by 29 private equity–backed groups from 2012 to October 2019, covering 1,466 locations and 2,146 doctors; 186 of the purchases came in 2017 to 2019 (Chen et al., Ophthalmology, 2020).
- In one study's Medicare sample, practices that private equity bought in 2017 and 2018 employed about 5% of the ophthalmologists and under 2% of the optometrists in 2019, by our calculation from the study's figures (Braun et al., Ophthalmology, 2024). The president of the American Academy of Ophthalmology put it at "as many as 8%" of ophthalmologists in 2022 (KFF Health News), and in a 2025 study of 18,672 ophthalmologists from 2016 to 2020, 3,129, about 17%, were affiliated (Bejarano et al., JAMA Ophthalmology, 2025).
- Retina is the exception: nearly 30% of retina specialists nationally are affiliated with private equity firms, according to a 2025 study (Singh et al., Health Affairs, 2025).
Where specialists are scarce
Most Americans live near an eye doctor: one study found 91% within a 30-minute drive of an ophthalmologist and 95% within 30 minutes of an optometrist (Franco and Pineda, Ophthalmology, 202400457-3/abstract)). An optometrist quoted by Review of Optometry said the study left out about a third of optometrists and ignored how long patients wait for an appointment (Review of Optometry). Counties are another matter: in 2021, 62.7% of U.S. counties had no practicing ophthalmologist outside the federal system, up from 60.7% in 2010 (Shah et al., Graefe's Archive, 2026). Subspecialists are scarcer still. A 2026 study identified about 2,500 fellowship-trained retina specialists in 2025, and found that a third of rural residents lived more than an hour's drive from one, against 1.6% of city residents (Franco et al., Retina, 2026; Review of Optometry).
Where only one or two practices have a given specialist, patients are sent there whoever owns it. Ownership then matters less for where a patient goes than for who controls the path from the first exam to the surgery and the bill, when one group owns both the general eye doctors and the specialists they refer to. The Government Accountability Office's 2025 review found that studies of private equity–owned physician practices showed higher commercial prices in some specialties, ophthalmology among them, and that the effects varied with how concentrated a market was (GAO).
The big groups
Location counts are each group's own or trade-press counts:
- EyeCare Partners, bought by Partners Group in 2019 for $2.2 billion, according to KFF Health News, says it had more than 700 locations in 18 states. After a debt restructuring in 2024 (EyeCare Partners, via Business Wire), it agreed in September 2026 to sell its optometry division, more than 300 offices under five regional names, to MyEyeDr., saying the proceeds would reduce debt and that it would keep its ophthalmology practices and surgery centers (EyeCare Partners, via Business Wire). The sale was expected to close in the fourth quarter, subject to regulatory approval.
- MyEyeDr., bought by Goldman Sachs's private equity arm in 2019 and now backed by Goldman Sachs Asset Management and Charlesbank, opened its 1,000th office in June 2026, in 29 states (Vision Monday, 2019; Charlesbank; Vision Monday, 2026).
- AEG Vision, backed by Riata Capital, had more than 400 practices in 28 states at the end of 2023; EyeSouth Partners, owned by Olympus Partners since 2022, more than 213 locations and 20 surgery centers; Keplr Vision, backed by Golub and Imperial, 278 locations (Vision Monday, trade press, April 2024; Shore Capital, on EyeSouth).
- Unifeye Vision Partners, whose founding investor is Waud Capital Partners, had 64 clinics and 19 surgery centers as of May 2025, when it borrowed from Morgan Stanley's private credit arm and PGIM to keep growing, and describes itself as a "physician-led" surgery-center operator (Waud Capital). It operates in California, Minnesota, North Dakota and Texas (Unifeye).
New buyers. Drug distributors have started buying eye practices. Cencora paid about $4.4 billion in January 2025 for about 85% of Retina Consultants of America, which the private equity firm Webster Equity Partners had formed in 2020 (Cencora, SEC filing; KFF Health News), and McKesson about $850 million in April 2025 for 80% of PRISM Vision (McKesson).
Why doctors sell
The reasons groups and their advisers give are scale and pressure. The number of ophthalmologists has been about the same since 1990, half of them are over 50, and demand from patients 65 and older is projected to grow 42% by 2030, according to the American Academy of Ophthalmology (Becker's ASC, citing the AAO). Michael Kroin, whose firm helps doctors sell practices to private equity, told KFF Health News that doctors face hospitals buying practices and insurance paperwork: "If you're not growing, it's going to be tough to survive and make a similar level of income as you had historically." The academy's president said investors can help practices with marketing and with negotiating prices for drugs and supplies (KFF Health News). Eye care also has a profitable sideline that insurance doesn't set the price of: upgrades such as laser-assisted cataract surgery and lens implants that reduce the need for glasses, which patients often pay for themselves (same source).
What eye care costs
The BLS price index for eyeglasses and eye care rose about 46% from September 2000 to September 2026, while consumer prices overall rose 94%. Since September 2019 it rose 15.4%, against 31.2% overall, and in the year to September 2026 it rose 1.1%, against 3.7% (BLS, eyeglasses and eye care; BLS, all items). That is the opposite of vet care and dental care, whose prices outran inflation. The index follows the price of comparable items and adjusts for quality, so it doesn't show whether patients are being sold costlier lenses, coatings or surgical upgrades than before, and it doesn't cover what Medicare pays for surgery.
Price change: eyeglasses and eye care and all consumer prices
What the evidence shows
The studies below compare practices private equity bought with similar practices it didn't; they show what changed after a purchase, not why.
- Commercial prices. A 2022 study of dermatology, gastroenterology and ophthalmology practices bought from 2016 to 2020 found that the amount insurers allowed per claim rose 11% and new patients rose 38%, across the three specialties together. In ophthalmology, allowed amounts and imaging rose; cataract surgeries and eye exams did not (Singh et al., JAMA Health Forum, 2022).
- Medicare. A study of 2012 to 2019 found little change in Medicare spending overall after purchases, and a 24% rise in the number of patients optometrists in those practices saw (Braun et al., Ophthalmology, 2024). Another found that after private equity bought retina practices, their use of the drug aflibercept rose 22% and Medicare's spending on it 21% (Singh et al., Ophthalmology, 202400563-8/abstract)).
- Unprofitable surgery. Doctors in retina practices bought by private equity did 19.6% fewer retinal-detachment repairs than matched doctors whose practices weren't bought. Medicare pays less than the surgery costs, and it has to be done quickly to save sight (Singh et al., Health Affairs, 2025). At one Michigan academic hospital, detachment surgeries rose among patients living near private equity–owned retina practices, a sign the cases may have moved there (Franco et al., Clinical Ophthalmology, 2025).
- Industry payments. Payments from drug and device makers to ophthalmologists fell about 18% after their practices were bought, a result that only just cleared the usual test of statistical significance; before the purchases, those doctors had received far more than others, on average about $13,950 a year against $2,950 (Bejarano et al., JAMA Ophthalmology, 2025).
- Who gets bought. A KFF Health News analysis found that private equity went on to invest in 43% of the 30 top Medicare prescribers of Lucentis, a retina drug costing about $1,300 a dose, and 23% of the top prescribers of Avastin, a far cheaper alternative used for the same diseases (KFF Health News).
- Referrals. We found no study measuring whether private equity–owned eye groups keep referrals inside their own practices and surgery centers. A study of hospitals that own doctors' practices found that patients became much more likely to be treated at the owning hospital (Baker, Bundorf and Kessler, via NBER).
Patients' accounts aren't evidence of a pattern, but they show what the debate is about. KFF Health News described a St. Louis patient who paid $3,000 out of pocket for an astigmatism upgrade during cataract surgery that she said didn't fix her astigmatism ("You're a cow among a herd," she said), and a Cincinnati patient, happy with his results, who said he paid more than $2,000 out of pocket per eye for laser-assisted surgery and hadn't known about the cheaper manual version, which the reporters described as just as effective. EyeCare Partners, which owns the St. Louis practice and later bought the Cincinnati one, declined to comment.
The other side of the counter
EssilorLuxottica, formed when the French lens maker Essilor merged with the Italian frame maker Luxottica in 2018, had €28.5 billion in revenue in 2025, about €12.8 billion of it in North America (Vision Monday). Its annual report lists (EssilorLuxottica, 2025 universal registration document):
- Lenses: Varilux, Crizal, Transitions, Stellest and Shamir.
- Frame brands it owns: Ray-Ban, Oakley, Persol, Oliver Peoples, Vogue Eyewear, Arnette, Costa and others.
- Brands it makes frames for under license: among them Armani, Burberry, Chanel, Coach, Michael Kors, Prada, Ralph Lauren, Tiffany and Versace.
- Stores: about 18,000 worldwide, including 1,098 LensCrafters, 591 Target Optical and 549 Pearle Vision locations and 3,131 Sunglass Hut stores.
- Insurance: EyeMed, which it says serves 85 million people.
It bought the streetwear brand Supreme in 2024, and Meta, its partner on Ray-Ban and Oakley smart glasses, bought just under 3% of the company in 2025 (annual report; Bloomberg Law). We found no reliable public estimate of its share of U.S. lens or frame sales.
VSP Vision, which reports more than 85 million members, calls itself the largest not-for-profit vision benefits company (VSP Vision, 2024 impact report; CalChamber), though the IRS revoked its federal tax exemption effective 2003 (20/20). It, too, sits on several sides: it owns the frame maker Marchon, the Visionworks and Eyemart Express chains and VSP Optics labs (VSP Vision), and in December 2025 it completed its purchase of the Italian frame maker Marcolin, which makes Tom Ford and Guess frames (FashionUnited). Among the independent chains, National Vision, which runs America's Best, had about 1,250 stores in 2025 (National Vision, via Business Wire), and Warby Parker 323 (Warby Parker, SEC filing).
The fights. In 2012 60 Minutes asked why glasses cost so much. In a letter to customers after the broadcast, Luxottica USA's chief executive, Andrea Dorigo, wrote that Luxottica made "only a fraction of the 150 million frames and sunglasses sold every year" and that it had "never tried to abuse" its leadership position (20/20). A 2024 class action accused EssilorLuxottica of monopolizing premium eyewear. A federal judge dismissed it in September 2025, finding that the market it described lumped together lenses, frames and sunglasses, which aren't substitutes for one another. On October 30, 2026 the U.S. Court of Appeals for the Second Circuit affirmed, finding that the plaintiffs had defined "premium" by who sold the frames rather than by price (A&O Shearman; MLex).
Contact lenses
Four makers, Johnson & Johnson, Alcon, CooperVision and Bausch + Lomb, sell about 95% of the world's contact lenses, Cooper Companies' chief executive estimated in 2018 (Cooper Companies). After the makers set minimum retail prices for some lenses in 2013 and 2014, buyers sued; the four makers and a distributor settled for a combined $118 million by 2022, and Johnson & Johnson and Alcon did so without admitting liability (settlement site; MedTech Dive). A 2003 federal law requires eye doctors to give patients their contact lens prescription so they can buy lenses elsewhere (Fairness to Contact Lens Consumers Act), and in 2020 the FTC added a rule that patients sign to confirm they got it, over optometrists' objections (Vision Monday).
The rules
California law keeps optometrists and optical sellers apart. It bars optometrists from sharing ownership or profits with optical companies or dispensing opticians, and bars dispensing opticians from employing them (Cal. Bus. & Prof. Code § 655; § 2556). Optical chains challenged the rules and lost in a federal appeals court in 2012 (National Association of Optometrists and Opticians v. Harris). A 2015 law let optometrists lease space in optical stores if they own and fully control their practice, including its fees, staff and scheduling; LensCrafters, Walmart and the state optometric association supported it, and the state Board of Optometry opposed it (California Senate analysis).
California's 2025 law limiting private equity's control of medical and dental practices took effect January 1, 2026. It bars private equity groups and hedge funds from interfering in doctors' clinical judgment, including decisions on referrals, and from controlling business matters such as coding and billing. It covers physician practices, so ophthalmology is included, but it doesn't mention optometrists (SB 351). The dental part of this series describes the law in more detail.
Where the analogy breaks
Supermarket shoppers see prices, compare stores and judge the food. Eye patients often pay through a vision plan's allowance, can't judge for themselves whether a surgical upgrade is worth it, and are often sent to a practice by another doctor or in an emergency, without knowing who owns it, as KFF Health News found.
What people argue about
Scale. Kroin argues that practices need to grow to compete with hospitals and cope with insurers, and the academy's president credited investors with helping practices market themselves, expand and negotiate prices for drugs and supplies (KFF Health News). Unifeye, for one, describes itself as physician-led. On eyewear, Luxottica said in 2012 that it had never tried to abuse its position.
Profit over care. The same academy president warned that the drive to maximize profit risks compromising care, and Aditi Sen of the Health Care Cost Institute said the firms "are not selecting practices randomly." Lawrence Casalino of Weill Cornell Medicine doubted that most practices are "so inefficient that you can get 20% more profit out of them" and warned that the model depends on reselling to a buyer who pays more (KFF Health News). Critics point to the retinal-detachment study; others point to the flat Medicare spending in another study and to eye care's slow price growth.
What's unsettled. No study has measured referral patterns inside the groups, the 2022 commercial-price study didn't publish separate ophthalmology figures in its main text, and no public data show how much of the U.S. lens and frame market EssilorLuxottica holds. And EyeCare Partners said it would use the proceeds of its optometry sale to reduce debt, so the groups' own finances are part of the story.
See also
- The name on the dentist's door: the same buying in dentistry, part 2 of this series.
- The name over the counter: how a few companies came to sit on several sides of the prescription business, the next part.
- Where the money goes: who supplies the money behind the buying, the last part of this series.
Sources
- Size: BLS, Quarterly Census of Employment and Wages, optometrists' offices, establishments and employees; BLS, optometrists; Chen et al., Ophthalmology, 2020; Braun et al., Ophthalmology, 2024; Bejarano et al., JAMA Ophthalmology, 2025; Singh et al., Health Affairs, 2025.
- Access: Franco and Pineda, Ophthalmology, 202400457-3/abstract); Review of Optometry; Shah et al., Graefe's Archive, 2026; Franco et al., Retina, 2026; Review of Optometry, on county and retina access; GAO-25-107450.
- The groups: EyeCare Partners, via Business Wire, on its 2024 refinancing and optometry sale (September 28, 2026); MyEyeDr., via Business Wire; Charlesbank; Vision Monday on MyEyeDr. in 2019 and in 2026 (June 2026); Shore Capital, via Business Wire; Vision Monday, April 2024; Waud Capital (May 2025); Unifeye; Cencora, SEC filing (January 2025); McKesson (April 2025).
- Why doctors sell: Becker's ASC; KFF Health News (September 19, 2022).
- Prices: BLS consumer price index, eyeglasses and eye care and all items.
- Evidence: Singh et al., JAMA Health Forum, 2022; Singh et al., Ophthalmology, 202400563-8/abstract); Franco et al., Clinical Ophthalmology, 2025; Baker, Bundorf and Kessler, via NBER.
- Eyewear: Vision Monday; EssilorLuxottica, 2025 universal registration document; Bloomberg Law (July 2025); VSP Vision, 2024 impact report; CalChamber; 20/20 on VSP's tax status and Luxottica's answer to 60 Minutes (2012); VSP Vision; FashionUnited (December 2025); National Vision, via Business Wire; Warby Parker, SEC filing; A&O Shearman; MLex (October 30, 2026).
- Contact lenses: Cooper Companies (June 2018); contact lens settlement; MedTech Dive; Fairness to Contact Lens Consumers Act (2003); Vision Monday (June 2020).
- California: Bus. & Prof. Code § 655 and § 2556; Ninth Circuit, 2012; Senate analysis of AB 684 (2015); SB 351.